Sign up United Kingdom
AusCann Group Holdings Ltd (ASX:AC8)

AusCann Group Holdings Ltd (ASX:AC8)


Share Price
$ 0.88
Change
-0.015 (-1.69 %)
Market Cap
$270.45 m
Proactive Investors - Run By Investors For Investors

AusCann Group Holdings Ltd

AusCann is bringing together leading expertise and operations across all aspects of the medical cannabis value chain, beginning with cultivation and production, through to manufacture and distribution of products.

We are an Australian based company and our aim is to produce and provide high quality, economical and clinically validated cannabis medicines to Australian patients.

We...

EPIC: AC8
Market: ASX:AC8
52-week High/Low: A$1.86 / A$0.38
Sector: Pharmaceuticals
Market Cap: A$270.45M
Website: www.auscann.com.au

AusCann Group Holdings Ltd

www.auscann.com.au

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in AusCann Group Holdings Ltd


AusCann Group Holdings Ltd Snapshot

WHAT WE DO
PARTNER
We partner with industry experts and existing leading market participants to build an operations spanning the entire medical cannabis value chain, enabling the delivery of high quality, economical and clinically validated cannabis medicines to Australian patients.

LICENCE
Through our partnerships we licence existing high quality plant genetics and proven medical cannabis medicines and formulations. The formulations from our partners Canopy Growth Corporation are already being used among an existing patient base of 24,000.

EDUCATION
We provide education to Australian medical practitioners on the therapeutic benefits of medical cannabis and the range of conditions and symptoms it can relieve. We will do this through our expertise and that of our partners expertise to deliver doctor engagement programs and awareness campaigns to establish medical cannabis treatments in Australia as a viable and respected medication.

CLINICAL TRIALS
Through clinical trials using already proven medical cannabis medications we will be able to provide Australian clinical evidence of the efficacy of our medical cannabis formulations and thereby rapidly encourage medical practitioners to begin prescribing the medication to their patients in need.

DR MAL WASHER
CHAIRMAN
MBBS, EX MEMBER OF THE HOUSE OF REPRESENTATIVES

Dr Washer was a Liberal member of the Australian House of Representatives from 1998 to 2013. He was educated at the University of Western Australia, graduating in 1970 with degrees in medicine and surgery. He was a general practitioner before entering politics & established a number of prominent medical centres in Western Australia. Mal was also past chair of the Alcohol and Other Drugs Council of Australia. He has extensive experience in agricultural and horticultural activities and currently operates a commercial avocado plantation in Western Australia bringing highly relevant medical and horticultural expertise and experience to AusCann.

ELAINE DARBY
MANAGING DIRECTOR
BSC(HONS) LLB(HONS

Elaine holds a Bachelor of Science in Biochemistry & Microbiology, Honours in Molecular Biology and a Bachelor of Laws. Previous roles have included as a lawyer with top tier corporate law firm Clayton Utz, Media and Communications Officer for an Australian Federal Member of Parliament, and Managing Director and Senior Winemaker of Aquila Estate Winery where she was an award winning wine-maker and also involved in international business development and marketing in territories including Singapore, Japan, Canada, the United Kingdom, and the United States.

CHERYL EDWARDES
INDEPENDENT NON-EXECUTIVE DIRECTOR
LLM, BA, GAICD

Cheryl was the former Attorney-General for Western Australia and Minister for the Environment. Cheryl was most recently Executive General Manager for External Affairs, Government Relations and Approvals at Hancock Prospecting-a company associated with one of Australia’s wealthiest individuals.

Cheryl has extensive experience of successful negotiations to ensure that critical primary agreements and government approvals are obtained in a timely fashion. Such agreements and approvals include the Roy Hill Rail State Agreement and the Special Railway Licence; Port Lease and Licence; Native Title Agreements; Environmental Approvals, State and Federal; and many other critical approvals for Hancock Prospecting Pty Ltd and Roy Hill Iron Ore and Infrastructure.

MR BRUCE LINTON
NON-EXECUTIVE DIRECTOR
BPA

Mr Bruce Linton is the founder, Chairman and CEO of Canopy Growth Corporation, one of the world’s leading medical cannabis companies. Canopy Growth, through its subsidiaries Tweed and Bedrocan Canada, is the world’s largest producer of legal cannabis, and recently entered into a strategic partnership with AusCann.

Bruce has more than ten years of senior executive experience in the high-tech sector as a founder, executive and board member.  He has a proven track record of international success, working extensively with the World Bank and the Asia Development Bank. Bruce enjoys a high profile in the global medicinal cannabis sector and has a demonstrable track record of raising the capital required to build large scale cannabis business.

Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use